These results suggest that ICAM-1, MMP-3, IL-6, VEGF, and CRP might be useful surrogate markers to monitor improvement in the signs and symptoms of JIA and joints with active arthritis after initiation of treatment with infliximab + MTX therapy. This evidence concerns the gene ICAM1 and Arthritis.